Michaelson MD - Search Results

1

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?

Gao X, McDermott DF, Michaelson MD. Gao X, et al. Among authors: michaelson md. Oncologist. 2019 Jun;24(6):725-727. doi: 10.1634/theoncologist.2019-0165. Epub 2019 Apr 29. Oncologist. 2019. PMID: 31036769 Free PMC article.

2

Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).

De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC. De Bazelaire C, et al. Among authors: michaelson md. Acad Radiol. 2005 Mar;12(3):347-57. doi: 10.1016/j.acra.2004.12.012. Acad Radiol. 2005. PMID: 15766695 Clinical Trial.

3

Sunitinib in patients with metastatic renal cell carcinoma.

Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD. Motzer RJ, et al. Among authors: michaelson md. JAMA. 2006 Jun 7;295(21):2516-24. doi: 10.1001/jama.295.21.2516. JAMA. 2006. PMID: 16757724 Clinical Trial.

4

ASCO 2006 highlights: targeted therapy for renal cell carcinoma.

Michaelson MD. Michaelson MD. Cancer Treat Rev. 2007 Jun;33(4):381-90. doi: 10.1016/j.ctrv.2007.01.002. Epub 2007 Mar 23. Cancer Treat Rev. 2007. PMID: 17367939

5

Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma.

Michaelson MD, Iliopoulos O, McDermott DF, McGovern FJ, Harisinghani MG, Oliva E. Michaelson MD, et al. N Engl J Med. 2008 May 29;358(22):2389-96. doi: 10.1056/NEJMcpc0802449. N Engl J Med. 2008. PMID: 18509125 No abstract available.

6

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, Rofsky NM. de Bazelaire C, et al. Among authors: michaelson md. Clin Cancer Res. 2008 Sep 1;14(17):5548-54. doi: 10.1158/1078-0432.CCR-08-0417. Clin Cancer Res. 2008. PMID: 18765547 Clinical Trial.

7

New treatments for renal cell carcinoma: targeted therapies.

Saylor PJ, Michaelson MD. Saylor PJ, et al. Among authors: michaelson md. J Natl Compr Canc Netw. 2009 Jun;7(6):645-56. doi: 10.6004/jnccn.2009.0045. J Natl Compr Canc Netw. 2009. PMID: 19555586 Review.

8

Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?

Saylor PJ, Michaelson MD. Saylor PJ, et al. Among authors: michaelson md. Oncologist. 2012;17(2):288-90. doi: 10.1634/theoncologist.2011-0433. Epub 2012 Jan 20. Oncologist. 2012. PMID: 22267850 Free PMC article.

9

Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.

Saylor PJ, Escudier B, Michaelson MD. Saylor PJ, et al. Among authors: michaelson md. Clin Genitourin Cancer. 2012 Jun;10(2):77-83. doi: 10.1016/j.clgc.2012.01.010. Epub 2012 Feb 28. Clin Genitourin Cancer. 2012. PMID: 22382009 Review.

10

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ. Cho DC, et al. Among authors: michaelson md. Cancer. 2012 Dec 15;118(24):6055-62. doi: 10.1002/cncr.27668. Epub 2012 Jun 6. Cancer. 2012. PMID: 22674198 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

134 results

Search Page